11/18
08:00 am
mbx
MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
Medium
Report
MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
11/7
08:00 am
mbx
MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
10/28
08:00 am
mbx
MBX Biosciences to Participate in Upcoming November Investor Conferences
Medium
Report
MBX Biosciences to Participate in Upcoming November Investor Conferences
10/8
07:32 am
mbx
MBX Biosciences, Inc. (NYSE: MBX) is now covered by analysts at Guggenheim. They set a "buy" rating and a $44.00 price target on the stock.
High
Report
MBX Biosciences, Inc. (NYSE: MBX) is now covered by analysts at Guggenheim. They set a "buy" rating and a $44.00 price target on the stock.
10/8
07:32 am
mbx
MBX Biosciences, Inc. (NYSE: MBX) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $30.00 price target on the stock.
High
Report
MBX Biosciences, Inc. (NYSE: MBX) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $30.00 price target on the stock.
10/8
07:32 am
mbx
MBX Biosciences, Inc. (NYSE: MBX) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $35.00 price target on the stock.
High
Report
MBX Biosciences, Inc. (NYSE: MBX) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $35.00 price target on the stock.
10/8
07:32 am
mbx
MBX Biosciences, Inc. (NYSE: MBX) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $40.00 price target on the stock.
High
Report
MBX Biosciences, Inc. (NYSE: MBX) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $40.00 price target on the stock.
9/30
08:00 am
mbx
MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting
Medium
Report
MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting
9/16
04:05 pm
mbx
MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Low
Report
MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
9/13
02:03 pm
mbx
Biotech IPO Shares Climb in Trading Debuts After Deals Upsized [Yahoo! Finance]
Medium
Report
Biotech IPO Shares Climb in Trading Debuts After Deals Upsized [Yahoo! Finance]
9/13
12:58 am
mbx
Bicara Leads Trio of US Biotech IPOs Raising $703 Million [Yahoo! Finance]
Low
Report
Bicara Leads Trio of US Biotech IPOs Raising $703 Million [Yahoo! Finance]
9/12
07:11 pm
mbx
MBX Biosciences Announces Pricing of Initial Public Offering
Low
Report
MBX Biosciences Announces Pricing of Initial Public Offering